ID   1205Lu
AC   CVCL_5239
SY   1205-Lu; 1205 Lu; WM 1205LU; WM-1205LU; WM1205Lu; WM1205; LU1205; Lu1205; WC00058
DR   BTO; BTO:0005011
DR   CLO; CLO_0001056
DR   EFO; EFO_0002810
DR   ATCC; CRL-2812
DR   BioSample; SAMN03471797
DR   cancercelllines; CVCL_5239
DR   Cell_Model_Passport; SIDM00972
DR   Coriell; WC00058
DR   Cosmic; 686410
DR   Cosmic; 905861
DR   Cosmic; 972275
DR   Cosmic; 1155274
DR   Cosmic; 1155554
DR   Cosmic; 1187583
DR   Cosmic; 1303026
DR   Cosmic; 1507616
DR   ESTDAB; ESTDAB-067
DR   GEO; GSM109020
DR   GEO; GSM109021
DR   GEO; GSM188067
DR   GEO; GSM188119
DR   GEO; GSM188192
DR   GEO; GSM188207
DR   GEO; GSM188218
DR   GEO; GSM188283
DR   GEO; GSM188292
DR   GEO; GSM952578
DR   LINCS_LDP; LCL-1236
DR   Lonza; 900
DR   PRIDE; PXD004343
DR   Progenetix; CVCL_5239
DR   Rockland; 51603
DR   SKY/M-FISH/CGH; 4946
DR   Wikidata; Q54581163
RX   DOI=10.4172/1948-5956.1000196;
RX   DOI=10.4172/1948-5956.1000401;
RX   PubMed=2068080;
RX   PubMed=8342600;
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=18790768;
RX   PubMed=25950383;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
WW   https://web.archive.org/web/20170706193814/http://www.rockland-inc.com/Product.aspx?id=51603
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Partially contaminated. The stock formerly distributed by Coriell (WC00058) contains a significant amount of mouse DNA (DOI=10.4172/1948-5956.1000196). This is not the case of the original Wistar stock which was distributed by Rockland (DOI=10.4172/1948-5956.1000401).
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00483.
CC   Population: Caucasian.
CC   Characteristics: Established from serial passaging of the parent cell line through immune deficient mice and harvesting lung metastasis.
CC   HLA typing: A*01:01,29:01; B*35:01,57:01; C*06:02,04:01:01; DPB1*04:01,04:01; DQB1*03:01:01,03:01:01; DRB1*11:03:01,11:03:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; Wistar).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Unspecified (Wistar).
CC   Omics: Deep proteome analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: Amelogenin: X,Y->X, D16S539: 11,12->10,12, D7S820: 10,12->10, D8S1179: 11,12,14->12,14 and vWA: 16,17->17.
CC   Discontinued: ATCC; CRL-2812; true.
CC   Discontinued: Coriell; WC00058; probable.
CC   Discontinued: Rockland; 51603; true.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): ATCC; ESTDAB; Wistar
ST   Amelogenin: X (Wistar)
ST   Amelogenin: X,Y (ATCC; ESTDAB)
ST   CSF1PO: 11
ST   D13S317: 8,14
ST   D16S539: 10,12 (Wistar)
ST   D16S539: 12 (ATCC)
ST   D18S51: 14,15
ST   D19S433: 13,15
ST   D21S11: 28,29
ST   D2S1338: 17,24
ST   D3S1358: 14,16
ST   D5S818: 10,12
ST   D7S820: 10 (Wistar)
ST   D7S820: 10,12 (ATCC; ESTDAB)
ST   D8S1179: 12,14
ST   FGA: 20,21
ST   TH01: 6,8
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8787 ! WM793
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   DOI=10.4172/1948-5956.1000196;
RA   Nair H.B., Bhaskaran S., Pathak S., Ghosh R., Betty D., Moore C.M.,
RA   VandeBerg J.L.;
RT   "1205Lu human metastatic melanoma cells, not human!";
RL   J. Cancer Sci. Ther. 5:119-119(2013).
//
RX   DOI=10.4172/1948-5956.1000401;
RA   Brafford P., Sproesser K., Krepler C., Herlyn M.;
RT   "1205Lu is human melanoma depending on the source.";
RL   J. Cancer Sci. Ther. 8:113-113(2016).
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=8342600;
RA   Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K.,
RA   Herlyn D., Valyi-Nagy I.T., Herlyn M.;
RT   "Growth and invasion of human melanomas in human skin grafted to
RT   immunodeficient mice.";
RL   Am. J. Pathol. 143:528-537(1993).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431;
RA   Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B.,
RA   Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P.,
RA   Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.;
RT   "Increased cyclin D1 expression can mediate BRAF inhibitor resistance
RT   in BRAF V600E-mutated melanomas.";
RL   Mol. Cancer Ther. 7:2876-2883(2008).
//
RX   PubMed=25950383; DOI=10.1111/pcmr.12380;
RA   Lazar I., Clement E., Ducoux-Petit M., Denat L., Soldan V.,
RA   Dauvillier S., Balor S., Burlet-Schiltz O., Larue L., Muller C.,
RA   Nieto L.;
RT   "Proteome characterization of melanoma exosomes reveals a specific
RT   signature for metastatic cell lines.";
RL   Pigment Cell Melanoma Res. 28:464-475(2015).
//